Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 9 studies | 26% ± 13% | |
brain | 8 studies | 36% ± 18% | |
peripheral blood | 4 studies | 21% ± 5% | |
eye | 4 studies | 22% ± 4% | |
kidney | 4 studies | 18% ± 3% | |
pancreas | 3 studies | 24% ± 6% | |
intestine | 3 studies | 17% ± 1% | |
adipose | 3 studies | 20% ± 2% | |
liver | 3 studies | 16% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3633.02 | 244 / 245 | 100% | 9.18 | 501 / 502 |
kidney | 100% | 3423.94 | 89 / 89 | 99% | 8.49 | 895 / 901 |
breast | 100% | 4802.47 | 459 / 459 | 99% | 7.56 | 1106 / 1118 |
brain | 100% | 5128.62 | 2635 / 2642 | 99% | 5.00 | 696 / 705 |
thymus | 100% | 5936.16 | 653 / 653 | 98% | 9.30 | 590 / 605 |
adrenal gland | 100% | 4741.41 | 258 / 258 | 97% | 9.87 | 224 / 230 |
pancreas | 100% | 5930.45 | 328 / 328 | 97% | 7.46 | 173 / 178 |
liver | 100% | 3607.15 | 226 / 226 | 97% | 5.60 | 392 / 406 |
lung | 100% | 4559.55 | 577 / 578 | 96% | 6.87 | 1114 / 1155 |
stomach | 100% | 5011.89 | 359 / 359 | 93% | 5.03 | 267 / 286 |
esophagus | 95% | 3163.27 | 1379 / 1445 | 95% | 5.63 | 174 / 183 |
uterus | 99% | 3870.65 | 169 / 170 | 88% | 4.13 | 402 / 459 |
intestine | 100% | 3808.39 | 966 / 966 | 85% | 4.36 | 449 / 527 |
ovary | 100% | 3061.93 | 180 / 180 | 85% | 3.22 | 365 / 430 |
skin | 98% | 2953.36 | 1778 / 1809 | 84% | 5.14 | 395 / 472 |
bladder | 100% | 3407.81 | 21 / 21 | 76% | 3.27 | 381 / 504 |
blood vessel | 100% | 8423.77 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 3399.36 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.02 | 1 / 1 |
adipose | 100% | 5177.06 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 5103.76 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 4099.35 | 830 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 6952.36 | 890 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 84% | 3.25 | 38 / 45 |
lymph node | 0% | 0 | 0 / 0 | 83% | 3.07 | 24 / 29 |
eye | 0% | 0 | 0 / 0 | 38% | 1.46 | 30 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_2001106 | Biological process | regulation of Rho guanyl-nucleotide exchange factor activity |
GO_0045787 | Biological process | positive regulation of cell cycle |
GO_0016020 | Cellular component | membrane |
GO_0005515 | Molecular function | protein binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | CCPG1 |
Protein name | Cell cycle progression protein 1 (Cell cycle progression restoration protein 8) Cell cycle progression 1 |
Synonyms | CPR8 KIAA1254 CCP8 |
Description | FUNCTION: Acts as an assembly platform for Rho protein signaling complexes. Limits guanine nucleotide exchange activity of MCF2L toward RHOA, which results in an inhibition of both its transcriptional activation ability and its transforming activity. Does not inhibit activity of MCF2L toward CDC42, or activity of MCF2 toward either RHOA or CDC42 (By similarity). May be involved in cell cycle regulation. . |
Accessions | ENST00000442196.8 [Q9ULG6-5] ENST00000310958.10 [Q9ULG6-1] ENST00000563171.5 H3BQN1 ENST00000568543.1 H3BN32 ENST00000568592.1 ENST00000570272.5 ENST00000564663.1 ENST00000425574.7 [Q9ULG6-3] H3BNE2 ENST00000568808.5 H3BV63 H3BR24 H3BTZ1 Q9ULG6 H3BPP4 ENST00000569205.5 [Q9ULG6-1] ENST00000564092.1 |